Universitaetsklinikum Aachen AöR
- Address
- lock Available on a paid plan
Operative Intensive Care and Intermediate Care at Universitaetsklinikum Aachen AöR
Clinical research here spans critical care, cardiovascular diseases, kidney disorders, and analytical and therapeutic techniques. The trials often focus on improving treatment effectiveness, refining diagnosis, and supporting recovery in seriously ill patients.
- Research in intensive care and critical illness, including sepsis, acute kidney injury, and postoperative complications
- Cardiovascular research on heart failure, atrial fibrillation, atherosclerotic disease, and surgical risk reduction
- Kidney-focused studies covering chronic kidney disease, IgA nephropathy, FSGS, and transplant-related care
The site also contributes to studies that test better ways to protect organs during major surgery and to improve outcomes for patients in complex hospital-based care.
Hematology and Stem Cell Transplantation
A major part of the trial portfolio addresses blood cancers, myeloproliferative neoplasms, and transplant medicine. Research is aimed at improving survival, reducing relapse, and making transplant-related treatment safer and more effective.
- Leukemia studies in AML, ALL, and CML, including treatment strategies for newly diagnosed and relapsed disease
- Lymphoma research for diffuse large B-cell lymphoma, Hodgkin lymphoma, and other aggressive subtypes
- Transplant and graft-versus-host disease studies focused on prevention, conditioning, and long-term care
At Universitaetsklinikum Aachen AöR, this field combines standard oncology care with trials exploring more personalized and less toxic treatment approaches.
Solid Tumors and Surgical Oncology
The site conducts extensive research in solid tumors, especially breast cancer, lung cancer, prostate cancer, gastrointestinal cancers, and gynecologic cancers. Many studies aim to improve survival before and after surgery or to test new combinations that strengthen cancer control.
- Breast cancer trials for early, locally advanced, and metastatic disease
- Prostate and bladder cancer studies, including work on recurrence, metastatic disease, and imaging-guided care
- Gastrointestinal and hepatobiliary cancer research involving gastric, pancreatic, colorectal, cholangiocarcinoma, and liver cancers
These trials reflect a strong interest in multimodal cancer treatment, with the goal of improving outcomes while supporting surgical decision-making.
Neurology, Psychiatry, and Cognitive Disorders
Research in this area covers neurological diseases and mental health conditions, with studies in epilepsy, Alzheimer’s disease, stroke, multiple sclerosis, and schizophrenia. The main purpose is to improve symptom control, slow disease progression, and support brain health over time.
- Epilepsy studies focused on reducing seizure frequency and improving long-term control
- Alzheimer’s disease research aimed at earlier detection and slowing cognitive decline
- Psychiatric and neuroinflammatory disorders including treatment-resistant schizophrenia, multiple sclerosis, and movement-related conditions
This research area shows a broad commitment to both neurological care and cognitive health across different stages of disease.
Autoimmune, Inflammatory, and Rare Disease Research
The trial portfolio also includes immune system diseases, inflammatory disorders, and several rare diseases. Studies are designed to better control inflammation, reduce organ damage, and improve quality of life in chronic conditions.
- Autoimmune kidney diseases such as lupus nephritis and IgA nephropathy
- Inflammatory skin and bowel diseases including ulcerative colitis, hidradenitis suppurativa, and prurigo nodularis
- Rare hematologic and mast cell disorders such as systemic mastocytosis, paroxysmal nocturnal hemoglobinuria, and myelofibrosis
These studies at Universitaetsklinikum Aachen AöR highlight an active interest in conditions where better targeted treatment options are still needed.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 26 therapeutic areas and 15 of 418 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 399 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 90 by active trials.
- 1Novartis Pharma AG9active
lock +89 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG19trials
lock +51 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaetsklinikum Aachen AöR
lock Showing 1 of 283 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 418 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 24 | Unknown | 2018-06-13 | 2026-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
